Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]
Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]